[顺铂、长春地辛和丝裂霉素C联合化疗治疗非小细胞肺癌]

[Combination chemotherapy including cisplatinum, vindesine and mitomycin C for non-small cell lung cancer].

作者信息

Hayashi Y, Kato M, Matsuura T, Yamada Y, Adachi S, Ito G, Yamamoto K, Takeuchi T

机构信息

First Dept. of Internal Medicine, Nagoya City University, School of Medicine.

出版信息

Gan To Kagaku Ryoho. 1990 Aug;17(8 Pt 1):1455-60.

PMID:2167632

Abstract

Thirty-five patients with non-small cell lung cancer (adenocarcinoma: 15, squamous cell: 15, large cell: 5, Stage I: 3, II: 1, IIIA: 8, IIIB: 5, IV: 18) were treated with combination chemotherapy, CDDP 80 mg/m2 day 1, VDS 3 mg/m2 days 1 & 8, and MMC 8 mg/m2 day 1. This regimen was repeated two times at intervals of four weeks. Sixteen partial responses were observed (response rate of 45.7%), and the median duration of survival for responders was 12.6 +/- 7.5 months and for nonresponders 10.1 +/- 4.8 months. Statistically there was no difference between them, but a survival from the onset of therapy of responders was significantly better (p less than 0.05) than that of non-responders. Toxicity was tolerable with myelosuppression, chemotherapy-induced nausea and vomiting.

摘要

35例非小细胞肺癌患者（腺癌15例、鳞癌15例、大细胞癌5例；Ⅰ期3例、Ⅱ期1例、ⅢA期8例、ⅢB期5例、Ⅳ期18例）接受联合化疗，顺铂80mg/m²第1天，长春地辛3mg/m²第1天和第8天，丝裂霉素8mg/m²第1天。该方案每4周重复2次。观察到16例部分缓解（缓解率45.7%），缓解者的中位生存期为12.6±7.5个月，未缓解者为10.1±4.8个月。统计学上两者无差异，但缓解者从治疗开始的生存期显著优于未缓解者（p＜0.05）。毒性反应可耐受，包括骨髓抑制、化疗引起的恶心和呕吐。